# Assessment of Prospective CYP2C19 Genotype Guided Dosing of Anti-Platelet Therapy in Percutaneous Coronary Intervention

> **NCT02508116** · NA · COMPLETED · sponsor: **University of Pennsylvania** · enrollment: 509 (actual)

## Conditions studied

- Acute Coronary Syndrome
- Cardiovascular Diseases

## Interventions

- **GENETIC:** CYP2C19 genotyping

## Key facts

- **NCT ID:** NCT02508116
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11
- **Primary completion:** 2017-05
- **Final completion:** 2017-08
- **Target enrollment:** 509 (ACTUAL)
- **Last updated:** 2018-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02508116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02508116, "Assessment of Prospective CYP2C19 Genotype Guided Dosing of Anti-Platelet Therapy in Percutaneous Coronary Intervention". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02508116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*